Close X
Attorney Spotlight

How did Mike DeAgro's experience co-founding a nonprofit advocacy organization lead to a career in the legal field? Find out more>


Close X


Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more

Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Life Sciences

Specialty Pharmacy & Pharmaceuticals

With 20 attorneys, we have one of the largest Specialty Pharmacy & Pharmaceuticals Practices in the country. Led by industry veterans who have experience as both in-house general counsel and outside counsel for national pharmacy, pharma service and pharmacy benefit management companies, our multi-disciplinary team serves as operational and transactional counsel to a majority of the nation's largest specialty pharmacies.

We are regularly engaged in significant transactions in the specialty pharmacy industry. We also provide practical business advice and legal guidance to help with trade and distribution matters facing clients within the pharmaceutical industry. Day-to-day, we assist clients in navigating and complying with the contractual, regulatory and operational requirements unique to the pharmaceutical industry, and we lead clients in audits and compliance reviews.

We counsel a variety of clients including:

  • Large and small specialty and home infusion pharmacies
  • Large and small specialty drug manufacturers
  • Private equity firms
  • Specialty Drug Distributors
  • Group purchasing organizations (GPOs)
  • Reimbursement hubs, prior authorization programs, financial assistance programs, and other pharma services companies
  • 340B covered entities

Areas of Focus

  • + Contracting, Regulatory & Operational

      • Guiding parties in moving new products from manufacturing to market, such as handling the business needs of the manufacturer, as well as negotiating agreements with various entities through the supply chain.
      • Negotiating, designing and contracting distribution networks.
      • Advising on multiple patient assistance, co-pay waiver and coupon programs.
      • Counseling manufacturers and pharmacies in moving drugs from the manufacturer to the pharmacy, physician or hospital, including structuring compliant GPO arrangements and negotiating contracts for administrative service fees and rebates.
      • Assisting in designing, negotiating and contracting protocol management programs including integration of pharmaceutical products into protocol programs.
      • Managing complex, licensure issues including multi-pharmacy change of ownership (CHOW) projects in all 50 states.
      • Supporting the contracting of preferred exclusive specialty pharmacy provider networks with payors, including national and regional health plans and pharmacy benefit managers.
  • + Mergers, Acquisitions & Dispositions

      • Supporting the evaluation, bid process and diligence involved in specialty pharmacy mergers and acquisitions by:
        • Identifying and analyzing risks associated with specialty pharmacy companies involved in transactions.
        • Analyzing regulatory implications of mergers and acquisitions and addressing issues related to dispositions.
      • Leading negotiations for mergers, tender offers, and stock and asset purchases and divestitures (both tax-free and taxable).
      • Structuring spinoffs and recapitalizations, management buyouts and other going-private transactions.
  • + Compliance & Investigations

      • Addressing enforcement and compliance issues as well as responding to legal and regulatory violations.
      • Advising on healthcare liability and risk management issues.
      • Advising on issues associated with implementing new reimbursement, prior authorization support, financial assistance and other pharma services and programs for limited distribution specialty drugs.
  • + Disputes

      • Providing dispute resolution strategies and support for contracting and reimbursement issues.
      • Enforcing non-competes and other business protection strategies.


View More

Related Experiences

View More

Related Professionals


Viewing 0 of 0 Results

View More


View More

Upcoming Events

Past Events

View More

Media Mentions

View More




Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.